Filing Details

Accession Number:
0001209191-16-150891
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-11-17 16:36:23
Reporting Period:
2016-11-15
Filing Date:
2016-11-17
Accepted Time:
2016-11-17 16:36:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1088856 Corcept Therapeutics Inc CORT Pharmaceutical Preparations (2834) 770487658
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1253886 G Patrick Enright C/O Longitude Capital Partners, Llc
800 El Camino Real, Suite 220
Menlo Park CA 94025
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-11-15 154,359 $9.55 14,362,573 No 4 S Indirect By LVP
Common Stock Disposition 2016-11-15 3,094 $9.55 191,864 No 4 S Indirect By LCA
Common Stock Disposition 2016-11-16 17,052 $9.51 14,345,521 No 4 S Indirect By LVP
Common Stock Disposition 2016-11-16 342 $9.51 191,522 No 4 S Indirect By LCA
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By LVP
No 4 S Indirect By LCA
No 4 S Indirect By LVP
No 4 S Indirect By LCA
Footnotes
  1. Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.7200. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected..
  2. Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). Patrick G. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein.
  3. Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein.
  4. Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.5450. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.